Sacroiliac Joint Fusion Market Report Scope & Overview:

The Sacroiliac Joint Fusion Market was valued at USD 998.46 Million in 2025 and is expected to reach USD 4.42 Billion by 2035, growing at a CAGR of 16.84% from 2026-2035.

The Sacroiliac Joint Fusion Market will see traction due to the rising prevalence of chronic lower back pain, growing recognition of sacroiliac joint dysfunction as a treatable cause, and improving insurance coverage for minimally invasive procedures. Surgery has shifted decisively toward minimally invasive techniques that offer smaller incisions, less pain, and faster recovery than open fusion. Additive manufacturing and 3D-printed titanium implants are improving osseointegration by mimicking native cancellous bone. Expanding Medicare and commercial payer coverage, together with migration of procedures into ambulatory surgical centers, continues to widen patient access. Growing surgeon training programs are further expanding the number of centers able to offer these procedures.

⮞In February 2026, SI-BONE received FDA 510(k) clearance for its iFuse INTRA Ti implant system and began an alpha launch the following week. The company also secured a New Technology Add-on Payment for iFuse TORQ TNT and a transitional pass-through payment for iFuse Bedrock Granite.

U.S. Sacroiliac Joint Fusion Market Outlook

The U.S. Sacroiliac Joint Fusion Market was valued at USD 372.84 Million in 2025 and is expected to reach USD 1.58 Billion by 2035, growing at a CAGR of 15.96% from 2026-2035.

The U.S. Sacroiliac Joint Fusion Market is expanding owing to broad reimbursement coverage, a large population with chronic lower back pain, and strong commercial activity by device manufacturers. Medicaid programs across most states and many Blue Cross Blue Shield plans cover minimally invasive sacroiliac joint fusion, supporting steady procedure growth. SI-BONE, Medtronic, Globus Medical, Orthofix, PainTEQ, and CornerLoc all compete actively in the country. Favorable Medicare reimbursement for office-based procedures and new technology payments for breakthrough-designated implants continue to improve the economics of treating sacroiliac joint dysfunction. Growing physician awareness of the condition also supports steady procedure volume growth nationwide.

⮞In October 2025, SI-BONE received FDA 510(k) clearance for navigation instruments that enhance procedural flexibility and allow iFuse Bedrock Granite and iFuse TORQ implants to be used within robotic surgical workflows. The clearance supports wider adoption among spine surgeons already using navigation platforms.

By Indication, Degenerative Sacroiliitis Leads, While Trauma Grows Fastest

The degenerative sacroiliitis segment dominated the Sacroiliac Joint Fusion Market in 2025, supported by high prevalence, growing disease awareness, and improving diagnostic capability for sacroiliac joint disorders. Published estimates place sacroiliac joint degeneration at around 25% of adult patients presenting with relevant symptoms. Fusion surgery is typically recommended for patients with chronic pain who fail to respond to conservative care such as physical therapy and injections. Rising diagnosis rates among aging populations, together with better imaging and diagnostic block protocols, continue to expand the treatable patient pool for this leading indication. Failed conservative care remains the most common pathway into surgical referral for these patients.

Trauma is the fastest-growing indication, covering pelvic ring injuries such as lateral compression, anteroposterior compression, and vertical shear-type fractures that disrupt the sacroiliac joint. These types of injuries generally require urgent surgery, and their complexity and severity continue to drive growth in procedures. The market potential for pelvic fragility and insufficiency fractures in patients suffering from osteoporosis is estimated to be in the order of USD 300 million. Sacropelvic implants such as SI-BONE’s iFuse TORQ TNT are driving rapid adoption by trauma surgeons treating these complex fractures. Reimbursement for eligible trauma cases is also driving adoption. Trauma case volumes are stable.

By Treatment Type, Surgery Leads, While Radiofrequency Ablation Grows Fastest

The surgery segment dominated the Sacroiliac Joint Fusion Market in 2025, driven by growing preference for minimally invasive fusion and its clinical advantages over open procedures. Minimally invasive surgery offers smaller incisions, reduced pain and scarring, shorter hospital stays, and faster recovery. A Washington State Health Care Authority report found minimally invasive sacroiliac joint fusion more effective than open fusion for reducing pain. Rising numbers of clinical studies supporting the minimally invasive approach, together with broad payer coverage and a growing base of trained surgeons, continue to reinforce this segment's leading revenue position. Implant innovation also continues to improve surgical outcomes.

Radiofrequency ablation is the fastest growing treatment method providing medium level of pain relief, and restoring function in a patient without using any device inside the body. Continuous, pulsed, and water-cooled methods of radiofrequency ablation create heat lesions blocking pain signals coming from the sacroiliac joint. The method will interest those patients who are non-surgical candidates or those who want to defer surgery because this treatment can be carried out in an outpatient pain center. Growing awareness of this disorder, increased research activities and a rise in the incidence of risk factors behind this condition are some major factors behind its high level of growth. Repeatability is the demand generation factor behind it.

⮞In March 2025, a published 12-month analysis of cooled radiofrequency ablation for chronic sacroiliac joint pain reported sustained pain reduction and improvements in quality-of-life measures, providing further clinical evidence for a nonsurgical treatment option for appropriately selected patients.

By End User, Hospitals Lead, While Ambulatory Surgical Centers Grow Fastest

The hospitals segment dominated the Sacroiliac Joint Fusion Market in 2025, reflecting the higher volume of surgeries performed in hospital settings and their capacity to manage complex cases. Hospitals provide operating rooms, imaging, anesthesia teams, and specialized staff needed for trauma fixation, revision procedures, and patients with significant comorbidities. They also deliver specialized longer-term care and rehabilitation support. Treatments performed in hospital settings are generally well reimbursed, and the United States alone has roughly 6,129 hospitals, sustaining this segment's leading share throughout the forecast period. Complex revision cases also remain concentrated in hospital settings. Teaching hospitals also anchor surgeon training.

Ambulatory surgical centers are the fastest-growing end user segment, supported by the rising number of centers and the suitability of minimally invasive sacroiliac fusion for same-day discharge. Centers for Medicare and Medicaid Services data shows hundreds of certified facilities in large states such as California, Florida, Georgia, and Texas, with numbers continuing to rise. These centers perform high procedure volumes in short periods, improving efficiency and lowering cost per case. Favorable outpatient reimbursement and growing physician ownership of surgical centers are expected to drive very strong segment growth. Lower facility costs and shorter procedure times also appeal strongly to payers.

⮞In December 2025, the Centers for Medicare & Medicaid Services finalized its 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment policies, establishing updated payment provisions for eligible outpatient services. This provides relevant reimbursement context for outpatient surgical providers, although it does not independently establish increased payment for sacroiliac joint fusion.

Regional Analysis

North America Sacroiliac Joint Fusion Market Insights

North America accounted for approximately 41.64% of the Sacroiliac Joint Fusion Market in 2025, the largest share among all regions, supported by advanced healthcare infrastructure, the presence of leading device companies, and expanding reimbursement coverage. The United States generates most regional revenue, with SI-BONE, Medtronic, Globus Medical, Orthofix, PainTEQ, CornerLoc, and Life Spine competing actively. Manufacturers pursue clinical studies, patent filings, product launches, and partnerships to grow share. Medicare reimbursement increases for office-based procedures and new technology payments for breakthrough-designated implants continue to improve procedure economics across the region. Strong surgeon training and proctoring networks further support broad regional adoption.

Canada contributes a growing share through public healthcare coverage and expanding spine surgery capability at academic centers, with SI-BONE reporting early iFuse procedures in the country. Mexico represents an emerging market, supported by private hospital networks and medical tourism for spine procedures. Across the region, the shift of procedures into ambulatory surgical centers and growing use of navigation and robotic workflows are reshaping care delivery. However, continued payer scrutiny of patient selection criteria and the need for diagnostic blocks before approval can slow procedure authorization in some cases. Standardized diagnostic block protocols may gradually ease this payer authorization burden somewhat.

⮞In June 2025, Wenzel Spine announced U.S. FDA clearance for its panaSIa Sacroiliac Joint Fusion System, an expandable implant designed for minimally invasive sacroiliac joint stabilization. The clearance broadened the available implant options for U.S. providers treating sacroiliac joint dysfunction.

Europe Sacroiliac Joint Fusion Market Insights

The region continues to rank second in terms of regional market size due to the presence of Germany, the United Kingdom, France, Italy, Spain, and Nordic countries, which have spine surgery networks and public healthcare systems that provide patients with access to the procedure. The key regional supplier of spine care solutions is Germany-based company SIGNUS Medizintechnik. In addition, SI-BONE has CE marks for iFuse, iFuse 3D, and iFuse TORQ used for sacroiliac joint dysfunction, adult spinal deformity, and pelvic fracture fixation. The European Medical Device Regulation has increased requirements for the quality of clinical evidence, thus supporting suppliers that possess long-term outcome data. National registries will facilitate outcome monitoring in several major European countries in the future.

Germany ranks first in the region due to a large orthopedic and spine surgery sector, strong device industry, and high procedure volumes. The United Kingdom, France, and Italy support the market due to well-developed neurosurgery and orthopedic networks, although the process of adoption may be delayed due to the requirement to conduct national health technology assessments. Spain and Nordic countries support stable demand due to university hospitals that have good equipment. Adoption of iFuse TORQ in Europe by SI-BONE has contributed to international revenue growth. However, budget limitations in public hospitals limit the rate of adoption of premium implant systems in several markets.

⮞In September 2026, a two-year follow-up of the Scandinavian SIFSO randomized clinical trial was published, reporting outcomes after minimally invasive sacroiliac joint fusion. The study adds European clinical evidence relevant to ongoing evaluation of surgical effectiveness, although crossover between trial groups limits direct comparisons with sham surgery.

Asia-Pacific Sacroiliac Joint Fusion Market Insights

Asia-Pacific is currently witnessing the highest growth rate in the Sacroiliac Joint Fusion Market, anticipated to record a CAGR of around 19.72% during the forecast period from 2026 to 2035, driven by a large patient pool, rapidly developing healthcare facilities, and growing investment by regional and international companies. China holds a significant share of the regional market, as its very large population creates the highest number of people at risk of chronic lower back pain associated with sacroiliac joint disorders. Availability and adoption of minimally invasive surgical options continue to increase across major Chinese hospitals. Domestic manufacturers are also entering this segment.

Japan continues to be an important market due to the factors like aging population, universal health care coverage, and robust orthopedic surgery capabilities. As per SI-BONE, Japan has an early adoption of the procedure. India is an emerging market with a large patient population and increasing private hospital facilities and more spine surgeons being trained. Both Australia and New Zealand have early adoption of minimally invasive technologies and actively conduct clinical research. South Korea provides advanced hospitals infrastructure and growing demand for minimally invasive spine surgeries in its major cities. Surgical training programs of the regional surgeons are also contributing to the surgical volume in major Asian markets.

MEA & Latin America Sacroiliac Joint Fusion Market Insights

The Middle East & Africa region represents a smaller but developing share of the Sacroiliac Joint Fusion Market, led by Gulf Cooperation Council states such as Saudi Arabia and the UAE, where investment in specialized orthopedic and spine centers is expanding treatment capacity. SI-BONE has reported early iFuse procedures in Saudi Arabia, South Africa, and Israel, reflecting growing regional reach. Medical tourism in Dubai is attracting patients seeking advanced spine procedures. South Africa anchors demand across the wider African continent through its private hospital sector, although limited specialist availability restricts adoption elsewhere. Government hospital investment may gradually improve regional access over the forecast period.

Latin America is experiencing steady growth, with Brazil leading the region owing to its large population, substantial private healthcare sector, and growing number of trained spine surgeons. Mexico and Argentina contribute through expanding private hospital networks and cross-border patient flows from North America. Colombia and Chile are also seeing rising adoption of minimally invasive spine techniques. However, the high cost of implant systems, limited public reimbursement for sacroiliac fusion, and currency volatility continue to restrain faster market growth across much of the region over the forecast period. Private insurance expansion may gradually improve treatment affordability for many more regional patients.

Market Dynamics

Growth Drivers: Rising Lower Back Pain Burden and Minimally Invasive Adoption

Growth in the Sacroiliac Joint Fusion Market is primarily attributed to the rising prevalence of chronic pain in the lower back, buttocks, groin, and lower extremities, together with growing recognition of sacroiliac joint dysfunction as a treatable cause. Sacroiliac joint degeneration affects roughly a quarter of adult patients with relevant symptoms, yet the condition has historically been underdiagnosed. Aging populations and rising participation in sports and physical activity are increasing injury rates, with over 3.5 million children aged 14 and above suffering sports injuries annually in the United States alone. These injuries frequently contribute to later sacroiliac joint problems in adults.

Growing adoption of minimally invasive surgical techniques is further reinforcing market growth. These procedures deliver smaller incisions, reduced pain and scarring, shorter hospital stays, and faster recovery than open fusion. Improving insurance coverage has been critical, with Medicaid programs in most U.S. states and many commercial plans now covering minimally invasive sacroiliac joint fusion. Technological advances including 3D-printed porous titanium implants that mimic native cancellous bone are improving osseointegration and clinical outcomes. Growing navigation and robotic integration is also making implant placement more precise and reproducible for surgeons. Shorter procedure times further improve overall operating room efficiency and case throughput.

⮞In May 2025, a prospective multicenter study published in the journal Spine evaluated sacroiliac joint fusion performed by interventional pain physicians following structured training by spine surgeons. The findings support further evaluation of physician training models as minimally invasive procedural adoption expands.

Restraints: Patient Selection Challenges and Procedure Costs

Diagnostic and patient selection challenges remain a key factor limiting market growth. Sacroiliac joint pain presents similarly to lumbar disc disease, facet joint pain, and hip pathology, making accurate diagnosis difficult without diagnostic injections and careful clinical examination. Many payers require documented failure of conservative care and positive diagnostic blocks before authorizing surgery, which extends the time from presentation to treatment. Variation in diagnostic protocols between physicians creates inconsistent referral patterns. These factors limit the number of patients who reach surgical treatment despite a large underlying symptomatic population. Referral patterns also vary widely between medical specialties and across individual regions.

High procedure and implant costs are another limiting factor, particularly in markets without established reimbursement pathways. Implant systems, navigation equipment, and specialized instruments require significant capital and per-case spending, which can be difficult to justify in budget-constrained public health systems. Competition from non-surgical alternatives including platelet-rich plasma injections, epidural steroid injections, and stem cell treatments offers patients lower-cost options that avoid surgical complications. The learning curve for surgeons adopting new approaches, together with regulatory requirements for clinical evidence, can also slow adoption in several international markets. Reimbursement gaps outside the United States compound this commercial challenge for many device manufacturers.

Opportunities: Trauma Applications and Ambulatory Procedure Growth

The expansion into pelvic trauma and fragility fracture fixation creates a significant opportunity for manufacturers. Pelvic fragility and insufficiency fractures in osteoporotic patients represent a market estimated at around USD 300 million, and purpose-built implants such as iFuse TORQ TNT have driven a threefold increase in trauma surgeons using sacropelvic solutions. New Technology Add-on Payments materially improve reimbursement for eligible cases. Sacropelvic fixation in adult spinal deformity surgery offers another large adjacent opportunity, with roughly 130,000 annual target procedures spanning adult deformity and degenerative spine cases. Breakthrough device designations further strengthen the commercial case for these highly specialized implant products.

At the same time, the migration of procedures into ambulatory surgical centers and expanding international access provide major growth opportunities. Office-based and outpatient settings benefit from improving Medicare reimbursement, and physician-owned centers are investing in spine capability. Growing navigation and robotic integration allows manufacturers to embed their implants within established surgical workflows. International expansion into Asia-Pacific, the Middle East, and Latin America, supported by distributor partnerships and surgeon training programs, can unlock large underpenetrated patient populations across these fast-developing healthcare markets. Local clinical evidence generation will be important to support favorable reimbursement decisions across many of these fast-emerging regional markets.

⮞In January 2026, Omnia Medical announced the commercial launch of its FDA-cleared PsiF DNA Sacroiliac Joint Stabilization System, designed for a minimally invasive posterior approach. The launch expanded commercially available implant options for treating sacroiliac joint dysfunction and created another product offering for providers evaluating posterior fusion techniques.

Sacroiliac Joint Fusion Market Key Players

• SI-BONE, Inc.

• Medtronic plc

• Globus Medical, Inc.

• Orthofix Medical Inc.

• PainTEQ, LLC

• CornerLoc

• SIGNUS Medizintechnik GmbH

• Life Spine, Inc.

• Camber Spine Technologies, LLC

• CoreLink Surgical

• Xtant Medical Holdings, Inc.

• Genesys Spine

• Zimmer Biomet Holdings, Inc.

• Tenon Medical, Inc.

• Omnia Medical, LLC

• Captiva Spine, Inc.

Sacroiliac Joint Fusion Market Report Scope: